RACGP examiner reports · fix it Not specific enough Naming the right idea without the dose, interval, threshold or number that earns the mark.
What it looks like: "Start an antibiotic" or "monitor closely" is the idea, not the answer. Marks go to the exact drug, dose, route, interval or threshold, and the options often differ only in those details.
How to fix it: When options differ only in a number, recall the number before you read them. Learn the doses, intervals and cut-offs from the local guidelines, not the general principle.
The drill: 15 questions Questions from the General practice bank picked because they test this habit. You answer one at a time and see the explanation straight away.
The first 3 are free, below and in the drill with a free account. Any General practice plan opens all 15.
Try 3 now. No account needed. Question 1 of 3 Palliative care
A palliative care patient is using a transdermal fentanyl patch at 25 micrograms/hour with good pain control, but nursing staff report that the patch will not stay attached because of sweating. The team decides to change to an alternative opioid at an equivalent dose. Which of the following is the most appropriate equivalent regimen? A Morphine 60 mg subcutaneously over 24 hours B Controlled-release oxycodone 20 mg orally twice daily C Immediate-release oxycodone 20 mg orally over 24 hours D Hydromorphone 24 mg orally over 24 hours E Buprenorphine 5 micrograms/hour transdermal patch weekly
Pick an answer to see the explanation. Next question →
Question 1 of 3 · Palliative care
A palliative care patient is using a transdermal fentanyl patch at 25 micrograms/hour with good pain control, but nursing staff report that the patch will not stay attached because of sweating. The team decides to change to an alternative opioid at an equivalent dose. Which of the following is the most appropriate equivalent regimen?
Morphine 60 mg subcutaneously over 24 hours Controlled-release oxycodone 20 mg orally twice daily Immediate-release oxycodone 20 mg orally over 24 hours Hydromorphone 24 mg orally over 24 hours Buprenorphine 5 micrograms/hour transdermal patch weekly Show the answer B. Controlled-release oxycodone 20 mg orally twice daily
Using the ANZCA Faculty of Pain Medicine opioid calculator, transdermal fentanyl 25 micrograms/hour is approximately equivalent to 60 mg oral morphine per 24 hours. Oral oxycodone is about 1.5 times as potent as oral morphine, so 40 mg oxycodone daily (controlled-release 20 mg twice daily) is equivalent to about 60 mg oral morphine. Many clinicians reduce the calculated dose by 25 to 50% for incomplete cross-tolerance when switching, but the controlled-release oxycodone option is the closest equivalent. Subcutaneous morphine is about 2 to 3 times as potent as oral morphine, so 60 mg subcutaneously per day corresponds to roughly 120 to 180 mg oral morphine, a large overdose. Immediate-release oxycodone 20 mg per day is only about 30 mg oral morphine equivalent and would leave her underdosed. Oral hydromorphone is about 5 times as potent as oral morphine, so 24 mg per day equals about 120 mg oral morphine. After removing a fentanyl patch, the subcutaneous depot continues to release drug for 12 to 24 hours, so the new regimen should be started cautiously. References: Faculty of Pain Medicine, ANZCA. Opioid Calculator. Melbourne: ANZCA. Therapeutic Guidelines. Palliative Care: Opioid conversion. Melbourne: Therapeutic Guidelines Limited.
Why not A: Subcutaneous morphine 60 mg per day equals about 120 to 180 mg oral morphine, a large overdose. Why not C: This is only about 30 mg oral morphine equivalent per day, an underdose. Why not D: Oral hydromorphone 24 mg per day equals about 120 mg oral morphine, double the requirement. Why not E: Buprenorphine 5 micrograms/hour is roughly 12 mg oral morphine per day, well below the current dose. Question 2 of 3 · Women's, sexual and reproductive health
A 22-year-old woman who has completed her HPV vaccination course asks her general practitioner about her future risk of cervical cancer and at what stage of life it is most often diagnosed. Based on current Australian cancer data, in which age group is the age-specific incidence rate of cervical cancer highest?
30 to 39 years 40 to 49 years 50 to 59 years 60 to 69 years 20 to 29 years Show the answer B. 40 to 49 years
Australian incidence data show that the age-specific rate of cervical cancer rises with age to a peak in women aged 40 to 49 years and then falls. This pattern reflects the long interval, usually a decade or more, between persistent oncogenic HPV infection and invasive cancer, and the effect of screening and vaccination in younger cohorts. Rates in women in their 30s are rising but have not yet peaked, while rates in the 50s and 60s are lower than the peak, although under-screened older women remain an important group in whom later-stage disease is found. The National Cervical Screening Program offers 5-yearly HPV testing, including self-collection, from 25 to 74 years. References: Cancer Australia. Cervical cancer in Australia statistics; Australian Institute of Health and Welfare. Cancer data in Australia.
Source: National Cervical Screening Program clinical guidelines (Cancer Council Australia), checked Nov 2026
Why not A: Incidence is rising through this decade but has not reached its peak. Why not C: Rates decline after the peak in the 40 to 49 year group. Why not D: Rates are lower than at the peak, although unscreened older women remain at risk. Why not E: Incidence is lowest in this group, now further reduced by HPV vaccination. Question 3 of 3 · Dermatology
Histology from an excision biopsy of a lesion on a 46-year-old woman's thigh shows invasive superficial spreading melanoma, Breslow thickness 0.8 mm, no ulceration, mitotic rate 1/mm2 and no lymphovascular invasion, with peripheral margins clear by 1.5 mm. She has no palpable lymph nodes. According to Australian melanoma guidelines, what is the most appropriate definitive surgical management?
No further surgery, as the margins are clear Re-excision with a 5 mm clinical margin Re-excision with a 1 cm clinical margin Re-excision with a 1 cm margin and sentinel node biopsy Re-excision with a 2 cm clinical margin Show the answer C. Re-excision with a 1 cm clinical margin
Australian guidelines recommend a 1 cm clinical margin for invasive melanoma up to 1.0 mm thick, 1 to 2 cm for 1.0 to 4.0 mm and 2 cm for melanoma over 4.0 mm; 5 to 10 mm is for melanoma in situ. Her 0.8 mm tumour therefore needs a 1 cm re-excision. Sentinel lymph node biopsy is discussed for melanoma thicker than 1.0 mm, or 0.8 to 1.0 mm with high-risk features such as ulceration, a high mitotic rate or lymphovascular invasion. She has none of these, which separates the key from the sentinel node option. Follow-up includes skin and node surveillance and sun-protection advice.
Why not A: A histologically clear but narrow margin does not meet the definitive margin for invasive melanoma. Why not B: A 5 to 10 mm margin is for melanoma in situ. Why not D: Sentinel node biopsy is considered from 0.8 mm only with high-risk features, which she does not have. Why not E: A 2 cm margin is for melanoma thicker than 4 mm and adds morbidity here. Create a free account to save your results and keep going →
Where the RACGP examiners flagged it All RACGP examiner reports →
Fellowship Ready is not affiliated with or endorsed by the RACGP. Not affiliated with the RACGP.